Edition:
United States

Axsome Therapeutics Inc (AXSM.OQ)

AXSM.OQ on NASDAQ Stock Exchange Global Market

3.15USD
20 Jul 2018
Change (% chg)

$0.05 (+1.61%)
Prev Close
$3.10
Open
$3.10
Day's High
$3.20
Day's Low
$3.10
Volume
8,409
Avg. Vol
33,475
52-wk High
$6.45
52-wk Low
$2.05

Latest Key Developments (Source: Significant Developments)

Axsome Therapeutics Initiates Phase 2 Trial Of Axs-05 In Major Depressive Disorder
Tuesday, 5 Jun 2018 07:00am EDT 

June 5 (Reuters) - Axsome Therapeutics Inc ::AXSOME THERAPEUTICS INITIATES PHASE 2 TRIAL OF AXS-05 IN MAJOR DEPRESSIVE DISORDER.AXSOME THERAPEUTICS INC - FIRST PATIENT ENROLLED IN ASCEND STUDY.AXSOME THERAPEUTICS INC - TOPLINE RESULTS FROM ASCEND TRIAL ARE EXPECTED IN SECOND HALF OF 2018.  Full Article

Axsome Therapeutics Reports Q1 Loss Per Share Of $0.19
Tuesday, 8 May 2018 07:00am EDT 

May 8 (Reuters) - Axsome Therapeutics Inc ::AXSOME THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.Q1 LOSS PER SHARE $0.19.AT MARCH 31, 2018, AXSOME HAD $26.6 MILLION OF CASH COMPARED TO $34.0 MILLION OF CASH AT DECEMBER 31, 2017.BELIEVES CURRENT CASH WILL BE SUFFICIENT TO FUND OPERATIONS, BASED ON CURRENT OPERATING PLANS, INTO Q3 OF 2019.  Full Article

Axsome Therapeutics Says Independent Committee Recommends Continuation Of Depression Trial
Thursday, 26 Apr 2018 07:00am EDT 

April 26 (Reuters) - Axsome Therapeutics Inc ::AXSOME THERAPEUTICS ANNOUNCES POSITIVE OUTCOME OF INTERIM ANALYSIS OF STRIDE-1 PHASE 3 TRIAL OF AXS-05 IN TREATMENT RESISTANT DEPRESSION.AXSOME THERAPEUTICS INC - SECOND INTERIM ANALYSIS ANTICIPATED SECOND HALF OF 2018 FOR EFFICACY.AXSOME THERAPEUTICS INC - INDEPENDENT DATA MONITORING COMMITTEE RECOMMENDS TRIAL CONTINUATION.AXSOME THERAPEUTICS INC - IDMC ALSO REVIEWED AVAILABLE SAFETY INFORMATION FROM STUDY AND INDICATED AXS-05 APPEARED SAFE AND WELL-TOLERATED.  Full Article

Axsome Therapeutics Reports Q4 Loss Per Share $0.31
Wednesday, 7 Mar 2018 07:00am EST 

March 7 (Reuters) - Axsome Therapeutics Inc ::AXSOME THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.Q4 LOSS PER SHARE $0.31.AXSOME THERAPEUTICS - BELIEVES CASH AT DEC 31, 2017 TO BE SUFFICIENT TO FUND ANTICIPATED OPERATIONS INTO Q3 2019.AT DECEMBER 31, 2017, AXSOME HAD $34.0 MILLION OF CASH COMPARED TO $36.6 MILLION OF CASH AT DECEMBER 31, 2016.  Full Article

Axsome Collaborates With A Nicotine Addiction Research Center For Phase 2 Trial Of AXS-05 In Smoking Cessation
Thursday, 14 Dec 2017 07:00am EST 

Dec 14 (Reuters) - Axsome Therapeutics Inc ::AXSOME THERAPEUTICS COLLABORATES WITH WORLD-LEADING NICOTINE ADDICTION RESEARCH CENTER FOR PHASE 2 TRIAL OF AXS-05 IN SMOKING CESSATION.AXSOME THERAPEUTICS - ‍ENTERED RESEARCH COLLABORATION WITH DUKE UNIVERSITY TO EVALUATE AXS-05 IN A PHASE 2 CLINICAL TRIAL IN SMOKERS ATTEMPTING TO QUIT​.AXSOME THERAPEUTICS INC - ‍PHASE 2 TRIAL INITIATION ANTICIPATED IN Q1 OF 2018 FOR AXS-05​.  Full Article

Sabby Management Reports A 5.52 Percent Passive Stake In Axsome Therapeutics
Monday, 4 Dec 2017 09:58am EST 

Dec 4 (Reuters) - Axsome Therapeutics Inc ::SABBY MANAGEMENT, LLC REPORTS A 5.52 PERCENT PASSIVE STAKE IN AXSOME THERAPEUTICS INC AS OF DEC 1 - SEC FILING.  Full Article

Axsome Therapeutics Announces AXS-07 For The Treatment Of Migraine
Tuesday, 28 Nov 2017 07:00am EST 

Nov 28 (Reuters) - Axsome Therapeutics Inc ::AXSOME THERAPEUTICS ANNOUNCES AXS-07 FOR THE TREATMENT OF MIGRAINE.AXSOME THERAPEUTICS INC - ‍PHASE 3 TRIAL ANTICIPATED IN 2018​.AXSOME THERAPEUTICS INC - AXS-07 HAS ‍POTENTIAL FOR "SUPERIOR" EFFICACY AS COMPARED TO CURRENT TREATMENTS​.AXSOME THERAPEUTICS INC - ‍U.S. FDA PRE-INVESTIGATIONAL NEW DRUG APPLICATION​ MEETING WRITTEN GUIDANCE RECEIVED.  Full Article

Axsome Therapeutics reports Q3 loss per share $0.27
Wednesday, 8 Nov 2017 07:00am EST 

Nov 8 (Reuters) - Axsome Therapeutics Inc :Axsome Therapeutics reports third quarter 2017 financial results.Q3 loss per share $0.27.Axsome Therapeutics Inc - ‍Believes its cash as of Sept. 30, 2017 will be sufficient to fund anticipated operations into Q1 of 2019​.  Full Article

Axsome Therapeutics says ‍interim efficacy analysis of phase 3 create-1 trial of AXS-02 in complex regional pain syndrome expected year-end 2017​
Thursday, 7 Sep 2017 07:00am EDT 

Sept 7 (Reuters) - Axsome Therapeutics Inc :Axsome Therapeutics - ‍interim efficacy analysis of phase 3 create-1 trial of AXS-02 in complex regional pain syndrome (CRPS) is expected year-end 2017​.Axsome Therapeutics Inc - ‍interim analysis results for Coast-1 are now also expected late December 2017 to early January 2018​.  Full Article

Axsome Therapeutics reports Q2 loss per share $0.30
Wednesday, 9 Aug 2017 07:00am EDT 

Aug 9 (Reuters) - Axsome Therapeutics Inc :Axsome Therapeutics reports second quarter 2017 financial results.Q2 loss per share $0.30.Q2 earnings per share view $-0.34 -- Thomson Reuters I/B/E/S.Axsome Therapeutics Inc - cash as of June 30, will be sufficient to fund anticipated operations, based on its current operating plans, into Q1 of 2019​.  Full Article

BRIEF-Axsome Therapeutics Reports Q1 Loss Per Share Of $0.19

* AXSOME THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE